Oxford BioMedica’s (OXB’s) interim results were broadly in line with our expectations for 2019. The decrease in H119 revenues to £32.1m (-9%) largely reflects the exceptional performance in the previous period, which was bolstered by strong licence income (H119: £13.3m vs H118: £19.9m) primarily from upfront payments with the Axovant and Bioverativ deals signed (£18.5m combined). Importantly, in H119 bioprocessing revenues grew 23% to £18.8m, which we
05 Sep 2019
Oxford Biomedica - Burgeoning bioprocessing revenues
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford Biomedica - Burgeoning bioprocessing revenues
Oxford BioMedica plc (OXB:LON) | 195 -4.3 (-1.1%) | Mkt Cap: 195.3m
- Published:
05 Sep 2019 -
Author:
Dr Daniel Wilkinson -
Pages:
2
Oxford BioMedica’s (OXB’s) interim results were broadly in line with our expectations for 2019. The decrease in H119 revenues to £32.1m (-9%) largely reflects the exceptional performance in the previous period, which was bolstered by strong licence income (H119: £13.3m vs H118: £19.9m) primarily from upfront payments with the Axovant and Bioverativ deals signed (£18.5m combined). Importantly, in H119 bioprocessing revenues grew 23% to £18.8m, which we